0000899243-16-016569.txt : 20160324
0000899243-16-016569.hdr.sgml : 20160324
20160324205208
ACCESSION NUMBER: 0000899243-16-016569
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160322
FILED AS OF DATE: 20160324
DATE AS OF CHANGE: 20160324
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 91 HARTWELL AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-676-2100
MAIL ADDRESS:
STREET 1: 91 HARTWELL AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Baumgartner Rudolph
CENTRAL INDEX KEY: 0001632878
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 161528529
MAIL ADDRESS:
STREET 1: C/O INOTEK PHARMACEUTICALS CORPORATION
STREET 2: 131 HARTWELL AVENUE, SUITE 105
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-03-22
0
0001281895
INOTEK PHARMACEUTICALS CORP
ITEK
0001632878
Baumgartner Rudolph
C/O INOTEK PHARMACEUTICALS CORPORATION
91 HARTWELL AVENUE, 2ND FLOOR
LEXINGTON
MA
02421
0
1
0
0
See Remarks
Stock Options (Right to Buy)
7.56
2016-03-22
4
A
0
165000
0.00
A
2026-03-21
Common Stock
165000
165000
D
The stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan"). 25% of the options granted shall vest on the one year anniversary of January 1, 2016 and 1/36th of the remaining option grant shall vest on each monthly anniversary thereafter, subject to continued service through such dates.
As previously reported on June 26, 2015, the Reporting Person was granted a stock option award under the Plan. The total beneficially owned derivative securities following the grant inadvertently included securities of a separate class, and accordingly such previously inadvertently reported shares are now properly excluded. In addition, the Price of Derivative Security reported on the June 26, 2015 Form 4 was inadvertently reported as $5.03 when it should have properly been recorded as $0.
Executive Vice President, Chief Medical Officer
/s/ Dale Ritter, Attorney-in-Fact for Rudolph Baumgartner
2016-03-24